Studies leading to the identification of ZD1839 (Iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Bioorganic and Medicinal Chemistry Letters

Volumn 11, Issue 14, 2001, Pages 1911-1914

  Barker, Andrew J ^a   Gibson, Keith H ^a   Grundy, Walter ^a   Godfrey, Andrew A ^a   Barlow, Jeffrey J ^a   Healy, Mark P ^a   Woodburn, James R ^a   Ashton, Susan E ^a   Curry, Brenda J ^a   Scarlett, Lynn ^a   Henthorn, Lianne ^a   Richards, Laura ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; TUMOR;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; KB CELLS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0035939330     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(01)00344-4     Document Type: Article

References (10)